Edgewise Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Edgewise Therapeutics, Inc. (EWTX) reported Increase Decrease In Operating Lease Liability of -$399.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$203.00K.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$196.00K.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$193.00K, a 165.65% decline year-over-year.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$189.00K.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$748.00K.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$220.00K.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$104.00K, a 103.56% decline from fiscal 2022.
- Edgewise Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was $2.92M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$203.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$399.00K 10-Q · filed 2026-08-06 | -$592.00K derived: sum of 3 quarters · filed 2026-08-06 | -$781.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$196.00K 10-Q · filed 2026-05-07 | -$389.00K derived: sum of 2 quarters · filed 2026-05-07 | -$578.00K derived: sum of 3 quarters · filed 2026-05-07 | -$765.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$382.00K derived: sum of 2 quarters · filed 2026-02-26 | -$569.00K derived: sum of 3 quarters · filed 2026-08-06 | -$748.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$376.00K derived: sum of 2 quarters · filed 2026-08-06 | -$555.00K 10-Q · filed 2025-11-06 | -$261.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$366.00K 10-Q · filed 2026-08-06 | -$72.00K derived: sum of 3 quarters · filed 2026-08-06 | -$251.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$179.00K 10-Q · filed 2026-05-07 | $115.00K derived: sum of 2 quarters · filed 2026-05-07 | -$64.00K derived: sum of 3 quarters · filed 2026-05-07 | -$235.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $115.00K derived: sum of 2 quarters · filed 2026-02-26 | -$56.00K derived: sum of 3 quarters · filed 2026-02-26 | -$220.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$350.00K derived: sum of 2 quarters · filed 2025-11-06 | -$514.00K 10-Q · filed 2025-11-06 | -$631.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$335.00K 10-Q · filed 2025-08-07 | -$452.00K derived: sum of 3 quarters · filed 2026-02-26 | -$555.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$164.00K 10-Q · filed 2025-05-08 | -$281.00K derived: sum of 2 quarters · filed 2026-02-26 | -$384.00K derived: sum of 3 quarters · filed 2026-02-26 | -$384.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$220.00K derived: sum of 2 quarters · filed 2026-02-26 | -$220.00K derived: sum of 3 quarters · filed 2026-02-26 | -$104.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$103.00K derived: sum of 2 quarters · filed 2024-11-07 | $13.00K 10-Q · filed 2024-11-07 | $1.79M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $116.00K 10-Q · filed 2024-08-08 | $1.89M derived: sum of 3 quarters · filed 2024-08-08 | $2.97M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $116.00K 10-Q · filed 2024-05-09 | $1.89M derived: sum of 2 quarters · filed 2024-05-09 | $2.97M derived: sum of 3 quarters · filed 2024-05-09 | $3.01M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.85M derived: sum of 2 quarters · filed 2024-02-22 | $2.90M derived: sum of 3 quarters · filed 2024-02-22 | $2.92M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.12M derived: sum of 2 quarters · filed 2023-11-09 | $1.14M 10-Q · filed 2023-11-09 | $1.11M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $67.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $24.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |